Scientists from the University of Helsinki, University of Eastern Finland, and University of Turku have mapped how various SARS-CoV-2 variants, including delta and omicron, hijack human cell processes to replicate and evade immune defenses. Their findings, published in Cell Discovery, offer critical insights for developing targeted antiviral treatments.
The study details the “hijackome”—a comprehensive mapping of how SARS-CoV-2 exploits specific cellular pathways. According to Professor Markku Varjosalo of the University of Helsinki, “Each variant has unique tactics for manipulating human cells. By identifying these mechanisms, we can pinpoint drug targets to block the virus’s spread.”
Using computational approaches developed by Professor Antti Poso and Dr. Ina Pöhner at the University of Eastern Finland, the researchers identified novel proteins that could serve as therapeutic targets to combat COVID-19.
Doctoral researcher Sini Huuskonen highlighted the practical implications of the study, noting that the findings could lead to improved treatments that reduce the severity of COVID-19 infections. Furthermore, the research helps advance personalized medicine by identifying variant-specific vulnerabilities, enhancing preparedness for future viral outbreaks.
As reported by medicalxpress, this breakthrough represents a significant step forward in global efforts to develop antiviral therapies, providing tools to limit viral replication and support public health in the ongoing fight against COVID-19 and emerging variants.